Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALON
2019-000716-28Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing Brolucizumab arm with Aflibercept arm (2 arms). Primary endpoint: Distribution of the last interval with no disease activity up to Week 32. Started Jun 2019; status: completed.
02
Drugs
brolucizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-000716-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000716-28.